Applying novel technologies to create better treatments

Taligen Therapeutics, Inc. is a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease. The Company employs novel technologies designed to modulate and regulate activation of the complement system. The complement system is a group of proteins which make up a critical component in the initiation of inflammation. Although complement activation and inflammation are a normal part of the body's defense against infection and injury, inappropriate complement activation leading to inflammation is a major contributor to a large number of human diseases.

Taligen’s technologies to regulate the excessive activation of complement can be applied to multiple inflammatory conditions. Taligen has proof of concept data in animal models of diseases as diverse as asthma, macular degeneration, immune renal disease, inflammatory arthritis, ischemia-reperfusion injury, stroke and traumatic brain injury. These diseases constitute major public health problems and significant unmet medical needs.

Learn more about our technology…